Back to News
Market Impact: 0.22
BioVie Doses Final Patient In Phase 2 Trial For Bezisterim In Long COVID; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsClinical Trials & Regulatory (Non-listed Theme)
BioVie (BIVI) dosed the last patient in the Phase 2 ADDRESS-LC trial for Bezisterim in treating neurological symptoms of Long COVID. The “last patient dosed” milestone is a positive clinical development, though no efficacy/safety or readout timeline was provided, suggesting modest near-term impact for the stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.12
Ticker Sentiment
BIVI0.25
More News
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one
- Blackstone President Jon Gray Bets Big on AI Boom
- What's behind the sell-off in AI neocloud stocks like CoreWeave and Nebius
- Giant Taiwanese chipmaker TSMC confirms it’s in talks with Elon Musk to join ‘Terafab’ complex in Texas: ‘The AI market continues to be very strong’